menu
    • menu

    Company profile for KYE Pharmaceuticals

    NEW Drugs in Dev: 2
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    KYE Pharmaceuticals is a private company headquartered in Canada focused on bringing medications to the Canadian market which fulfill clinically significant and unmet needs. KYE has licensed many innovative products and was founded on an entrepreneurial spirit that optimizes our team’s strengths and brings unique value to our partners, Canadian healthcare professionals, and most importantly, our patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    KYE PharmaceuticalsCanada Flag
    Country
    Country
    Canada
    Address
    Address
    KYE Pharmaceuticals Inc. 2233 Argentia Rd. Suites 302 & 302A, Mississauga ON, ...
    Telephone
    Telephone
    1-647-498-1533
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://kyepharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kye Pharma Licenses SLENYTO from Neurim for Canadian Market
    Kye Pharma Licenses SLENYTO from Neurim for Canadian Market

    13 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kye-pharmaceuticals-announces-licensing-and-distribution-agreement-with-neurim-pharmaceuticals-for-slenyto-in-canada-302658041.html

    PR NEWSWIRE
    13 Jan 2026
    Share Share
    Health Canada Greenlights Agamree For Duchenne DMD
    Health Canada Greenlights Agamree For Duchenne DMD

    02 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/health-canada-approves-agamree-vamorolone-as-the-first-treatment-for-duchenne-muscular-dystrophy-in-canada-302571841.html

    PR NEWSWIRE
    02 Oct 2025
    Share Share
    Kye Pharma’s Agamree Approved in Canada
    Kye Pharma’s Agamree Approved in Canada

    29 Sep 2025

    // HEALTH CANADA

    https://pdf.hres.ca/dpd_pm/00081910.PDF

    HEALTH CANADA
    29 Sep 2025
    Share Share
    Kye Pharmaceuticals wins approval for DYANAVEL® XR in ADHD
    Kye Pharmaceuticals wins approval for DYANAVEL® XR in ADHD

    06 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kye-pharmaceuticals-announces-the-approval-of-dyanavel-xr-amphetamine-extended-release-tablets-and-oral-suspension-for-the-treatment-of-adults-and-children-with-adhd-302519894.html

    PR NEWSWIRE
    06 Aug 2025
    Share Share
    Agamree Priority Review by Canada for Duchenne Muscular Dystrophy
    Agamree Priority Review by Canada for Duchenne Muscular Dystrophy

    08 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/08/3057585/13009/en/Catalyst-Pharmaceuticals-Announces-Health-Canada-s-Acceptance-of-AGAMREE-New-Drug-Submission-with-Priority-Review-for-Sub-Licensee-Kye-Pharmaceuticals.html

    GLOBENEWSWIRE
    08 Apr 2025
    Share Share
    Catalyst, KYE Announce Canadian Federal Court Ruling on Approval of Ruzurgi
    Catalyst, KYE Announce Canadian Federal Court Ruling on Approval of Ruzurgi

    11 Mar 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/03/11/2401826/13009/en/Catalyst-Pharmaceuticals-and-KYE-Pharmaceuticals-Announce-a-Second-Favorable-Canadian-Federal-Court-Ruling-Setting-Aside-Approval-of-Ruzurgi.html

    GLOBENEWSWIRE
    11 Mar 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search